Dr. Lal Path Labs Ltd.
Dr. Lal PathLabs Limited is one of India‚Äôs leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are…
What Dr. files
- Others57
- Investor Meet32
- Updates25
- Dividend/Bonus18
- Important18
- Board Meeting14
Lal PathLabs will hold its 32nd AGM online soon. The latest Annual Report is out; access links are being shared with members who haven't registered their email IDs, ensuring all receive information.
Dr. Lal PathLabs' FY25-26 BRSR shows strong compliance with no fines, safety incidents, or data breaches. The company invested 4.81 Cr in employee well-being and 8.38 Cr in CSR, while also improving energy efficiency and boosting renewable energy use.
NCLT approved the dissolution of its wholly-owned subsidiary, Suburban Diagnostics. Its business operations were previously consolidated. Suburban accounted for INR 164.03 Cr in turnover and INR 126.62 Cr in net worth (7.37% and 7.05% respectively) in the last fiscal year.
Dr. Lal PathLabs declared financial results: Q revenue at 730.6 Cr, profit 150.6 Cr. H1 revenue reached 1,400.4 Cr, profit 283.0 Cr. The board approved an INR 7 interim dividend and a 1:1 bonus share issue, pending shareholder approval. Operational changes included the liquidation of Suburban Diagnostics.
Dr. Lal PathLabs' Board approved acquiring immovable property in New Delhi, including office units and a ground-floor shop, for up to INR 74.51 Cr. This strategic acquisition enhances the company's operational infrastructure.